Pylarify 2026 - kent cboc
Active Awarded Last action
- Contract number
- 36C25026N0354
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,181,225
Award facts
- Contract value 100% obligated
- $1,181,225.28 Current and potential, with all options
- Completion date 64% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Bedford, MA 01730, USA
Award details come from SAM.gov/FPDS.
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $1.18 million by Veterans Integrated Service Network 10 on March 1, 2026, for the supply of PYLARIFY (piflufolastat F-18) radiopharmaceutical products to the Kent Community-Based Outpatient Clinic in Bedford, Massachusetts. The contract, designated as a Total Small Business set-aside, is structured on a firm fixed-price basis with an ultimate completion date of February 28, 2027, and operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). This delivery order supports the Veterans Health Administration's diagnostic imaging capabilities, enabling prostate cancer detection and localization through positron emission tomography (PET) scans for veteran patients receiving care within the VA healthcare system.
This award represents one of numerous delivery orders issued to Progenics Pharmaceuticals under its established framework agreements with the Veterans Integrated Service Networks. The awardee maintains a substantial federal contracting portfolio as a critical supplier of radiopharmaceuticals to the VA system, with multiple indefinite delivery vehicles and blanket purchase agreements valued in the millions of dollars. Progenics' parent company, Lantheus Holdings, Inc., holds a $290 million Federal Supply Schedule contract with VISN 12 extending through March 2030, which serves as a master vehicle facilitating efficient procurement of radiopharmaceutical products across multiple VA medical centers and the Defense Health Agency, underscoring the strategic importance of this product line to federal healthcare providers.
Quick answers
Who was awarded contract 36C25026N0354?
36C25026N0354 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 10 (Veterans Health Administration) on March 1, 2026.
How much is contract 36C25026N0354 worth?
The government has obligated $1,181,225 on 36C25026N0354.
Is contract 36C25026N0354 an order under another contract?
Yes. 36C25026N0354 is a delivery order under 36F79725D0093, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25026N0354 competed?
The extent of competition for 36C25026N0354 was full and open competition. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award